BT has thermal antihyperalgesic effects in chronic inflammatory and neuropathic pain models that are entirely PAP-dependent.

<p>(<b>A</b>) Inflammatory pain model. CFA was injected into the hindpaw of wild-type (n = 20) and <i>Pap^−/−</i> (n = 9) male mice, then BT (300 mg/kg, p.o.) was administered 1 day later. Thermal sensitivity monitored at the indicated times in the inflamed hindpaw. (<b>B</b>) Neuropathic pain model. The sural and common peroneal branches of the sciatic nerve were ligated and then transected in wild-type (n = 28) and <i>Pap^−/−</i> (n = 20) male mice. BT (300 mg/kg, p.o.) was administered 2 days later. Thermal sensitivity monitored at the indicated times in the nerve-injured hindpaw. T tests were used to compare responses between wild-type and <i>Pap^−/−</i> mice. *<i>P</i><0.05, **<i>P</i><0.005, ***<i>P</i><0.0005. Data are plotted as means ± s.e.m.